Treatment of acute viral hepatitis with (+)-cyanidanol-3.
A double-blind trial of (+)-cyanidanol-3 (2 g/day) versus placebo tablets was carried out in 100 patients with acute viral hepatitis. 51 received the drug and 49 placebo. (+)-Cyanidanol-3 accelerated the disappearance of HBsAg from the blood, lowered serum-bilirubin, and relieved symptoms such as anorexia, nausea, and pruritus. The drug was well tolerated. None of the patients had a relapse of acute hepatitis. Chronic active hepatitis developed in 1 of the placebo-treated patients. Thus, (+)-cyanidanol-3 seems to be of benefit in acute viral hepatitis.
D000328:Adult; D000469:Alkaline Phosphatase / Q000097:blood; D001219:Aspartate Aminotransferases / Q000097:blood; D001578:Benzopyrans / Q000627:therapeutic use*; D001663:Bilirubin / Q000097:blood; D002392:Catechin / Q000008:administration & dosage / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D005500:Follow-Up Studies; D006509:Hepatitis B / Q000188:drug therapy; D006511:Hepatitis B Antigens / Q000302:isolation & purification; D006525:Hepatitis, Viral, Human / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D008111:Liver Function Tests; D008297:Male; D008875:Middle Aged; D010919:Placebos; D011446:Prospective Studies
D001578:Benzopyrans; D006511:Hepatitis B Antigens; D010919:Placebos; D002392:Catechin; D001219:Aspartate Aminotransferases; D000469:Alkaline Phosphatase; D001663:Bilirubin